Paid Clinical Trials in Michigan

Candace Kastanis

Written by Candace Kastanis

Chemistry B.S. | UC Davis | Clinical Lab Technician

Clinical research in Michigan holds immense value in improving patient care. Through dedication, innovation, collaboration, and creativity, scientists create novel opportunities that can accommodate patients in the years to come.

Even now, the state of Michigan has a sizable history of successful clinical trials, innovations, and discoveries that have improved the quality of life and treatment outcomes for diverse patient groups.

Clinical Trials For Disease Areas in Michigan 

Michigan is a hub for cancer research. Clinical trials in the area target different types of cancers such as breast, lung, prostate, and leukemia. State experts are also studying treatments for neurological conditions. Such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. 

Clinical research trials in Michigan assess other diseases. Mainly infectious, respiratory, rare, and autoimmune disorders. Options such as these help diversify the pool of innovations and discoveries for creating personalized treatment plans.

Take a look at the list below to find future or active trials near you.

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Hickman Cancer Center, Adrian, Michigan +100 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Hickman Cancer Center, Adrian, Michigan +60 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796
Recruiting
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Hickman Cancer Center, Adrian, Michigan +71 locations
Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Hickman Cancer Center, Adrian, Michigan +49 locations
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141
Recruiting
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Hickman Cancer Center, Adrian, Michigan +17 locations
Conditions: Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Hickman Cancer Center, Adrian, Michigan +66 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046
Recruiting
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the abil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Hickman Cancer Center, Adrian, Michigan +1 locations
Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Register for Updates
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Hickman Cancer Center, Adrian, Michigan +64 locations
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Hickman Cancer Center, Adrian, Michigan +51 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499
Recruiting
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Hickman Cancer Center, Adrian, Michigan +22 locations
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
Register for Updates

There are lots of benefits to taking part in paid clinical trials in Michigan. By volunteering, you help develop medicines and treatments for the future. You also get paid for your time. 

The compensation for MI paid clinical trials varies based on the duration, phase of the trial, and the risks that come with it. This compensation can come in the form of financial gain or other benefits. 

Clinical Trials For Health Volunteers in Michigan

Volunteers from different backgrounds and races come together to provide comprehensive data to better understand a wide range of health issues. Both healthy and sick volunteers are welcome to help scientists collect valuable feedback. 

Back in 2018, a $45 million clinical trial was used to assess and study sleep apnea treatment in stroke survivors. Research teams in Michigan provided crucial data that can help the brain recover after a stroke.

If you want to volunteer for clinical trials, check the list below.

Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
Identification of Biomarkers for Stress Vulnerability and Resilience
NCT05498207
Recruiting
The purpose of this research study is to understand the biological mechanisms of stress vulnerability (being susceptible to stress) and stress resilience (being able to recover readily from stress), obtain biomarkers (a biological indicator) for stress resilience and to devise strategies for prevention and treatment of stress-related disorders.
Gender:
ALL
Ages:
Between 18 years and 22 years
Trial Updated:
06/26/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Healthy
Register for Updates
Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation
NCT06149780
Recruiting
To study the effect of fractionated 1927-nm non ablative thulium laser in reduction of post inflammatory hyperpigmentation (PIH) using a validated and reproducible model for studying PIH. * Determine if there is aa reduction in PIH in patients treated with three (3) monthly sessions of fractionated 1927-nm non ablative thulium laser * Determine if there is efficacy of post-procedure clobetasol propionate 0.05% ointment in the management of PIH * Determine the histological and molecular changes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Henry Ford Medical Center, Detroit, Michigan
Conditions: Healthy
Register for Updates
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
NCT06300697
Recruiting
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various time... Read More
Gender:
ALL
Ages:
Between 10 years and 55 years
Trial Updated:
09/17/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis, Food Allergy, Healthy
Register for Updates
The Impact of Light Exposure on Cognitive Function in Classrooms
NCT06325150
Recruiting
Humans are constantly exposed to a variety of light types, created naturally or through artificial means. Light exposure captured by the eyes impacts many physiological functions in humans, including but not limited to cognitive output, fatigue levels, and mood regulation. The level of impact on cognitive learning from different types of light on undergraduate adult students remains unclear.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Michigan State University, East Lansing, Michigan
Conditions: Healthy
Register for Updates
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
NCT06349473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
07/07/2025
Locations: University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Register for Updates
Adversity, Brain and Opioid Use Study
NCT06355778
Recruiting
The way people process and remember information may be related to adverse childhood experiences and Opioid Use Disorder symptoms. The purpose of this project is to examine brain function and performance during learning and memory tasks in adults. The study will compare measures of learning and memory across three groups of participants: those with an Opioid Use Disorder (OUD) that take buprenorphine for opioid replacement therapy, adults without an Opioid Use Disorder taking buprenorphine, and h... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/09/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Opioid Use Disorder, Healthy
Register for Updates
Multifocal HD-tDCS and Motor Function
NCT06561165
Recruiting
The purpose of this study is to understand how the brain controls movement and how Non-invasive Brain Stimulation (NIBS) with a technique called High-density transcranial direct current stimulation (HD-tDCS) can alter brain processes to improve behavior. Participants in this study will be randomized to either HD-tDCS with standard intervention or personalized dose-controlled multifocal network-targeted HD-tDCS. The hypothesis is that dexterous hand function will improve after a standard HD-tDCS... Read More
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
05/30/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Healthy
Register for Updates
A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
NCT07042191
Recruiting
The overall goal of this research program is to address financial toxicity through the development, testing, and implementation of a multi-level communication intervention. If successful, this intervention could be a companion intervention for Cancer providers in combination with the already in testing DISCO app (Discussions of Cost App) for patients. Participants will: * complete a baseline survey * attend two one on one meetings, one as part of the development and the second as part of the pi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/26/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Healthy, Financial Toxicity
Register for Updates
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629
Recruiting
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Epilepsy, Healthy Volunteer
Register for Updates

Medical Discoveries and Innovation in Michigan

The state of Michigan has an excellent reputation for conducting successful clinical research. The trials use superior technology, treatment, and tools to provide patients with the best possible care. Some of the most important medical discoveries made in Michigan include:

  • Artificial Heart: Researchers from the University of Michigan helped implant the First Total Artificial Heart in 1988. This is a remarkable milestone in the field of cardiac surgery. 
  • Multiple Sclerosis Therapies: In 1999, Dr. Sonda Rossman and Howard founded the MIND Multiple Sclerosis Center. It is one of the biggest private comprehensive centers for multiple sclerosis in the country. Their experts have been at the forefront of developing MS treatments and boosting the patient’s quality of life.
  • Stem Cell Research: Michigan researchers have made significant contributions to stem cell research. They explore the cell’s potential in regenerative medicine and disease treatment and have made notable progress.

Why Michigan Is A Great Place For Clinical Research 

The state has a relatively diverse population. This makes clinical research in Michigan a viable option for better treatment outcomes. According to MI population statistics, 74.2% of its residents are White, 13.8% are Black, 5.6% are Hispanic, 3.4% are Asian, 2.4% are multiracial, and 0.6% are American Indian.

Find Paid Clinical Trials

Find Paid Clinical Trials helps volunteers find paid research studies in their area. We track studies from ClinicalTrials.gov, with more than 22,000 actively recruiting across the United States.

Paid Clinical Trials By State

Alabama
Alaska
Arizona

California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Iowa

Indiana
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska

Nevada
New Hampshire
New Jersey
New Mexico

New York
North Carolina

North Dakota
Ohio
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota

Tennessee
Texas
Utah
Vermont

Virginia
Washington
Washington DC
West Virginia

Wisconsin
Wyoming

About Us
Contact
Privacy Policy
Terms of Use

© 2026 Find Paid Clinical Trials